RxDoctor Payments Data

Don Lee, MD

Interventional Cardiology · Glendale, CANPI 1104806421

Payments from drug & device makers

$27,949in general payments, 2019–2025

Across 1,147 payments — averaging $24.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$9K
  • Novartis$2K
  • Amgen$2K
  • Boehringer Ingelheim$2K
  • Esperion Therapeutics, Inc.$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • plus $10K from 38 others

What the payments were for

  • Food & beverage$18,51666%
  • Education$9,43434%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,949 in reported general payments places this provider in the 70th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$2,095,560
Medicare patients
1,426
Services billed
10,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban859$688,914
EntrestoSacubitril/Valsartan551$483,609
OpsumitMacitentan38$448,505
NexlizetBempedoic Acid/Ezetimibe881$415,863
XareltoRivaroxaban249$201,254
JardianceEmpagliflozin247$197,565
FarxigaDapagliflozin Propanediol236$180,861
Repatha PushtronexEvolocumab240$157,349
Repatha SureclickEvolocumab254$149,237
VascepaIcosapent Ethyl369$146,328
InpefaSotagliflozin156$102,297
CorlanorIvabradine Hcl157$100,867
LeqvioInclisiran Sodium32$98,511
MultaqDronedarone Hcl138$97,196
NexletolBempedoic Acid174$80,880

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$582$688,914859 claims
NovartisEntresto, Leqvio$2,376$582,120583 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$1,204$496,7431,055 claims
Actelion Pharmaceuticals US, Inc.Opsumit$620$448,50538 claims
AstraZenecaFarxiga, Brilinta, Crestor$970$247,405363 claims
Johnson & JohnsonXarelto$860$201,254249 claims
Boehringer IngelheimJardiance$1,819$197,565247 claims
Lexicon Pharmaceuticals, Inc.Inpefa$664$102,297156 claims
AmgenCorlanor$1,863$100,867157 claims
Sanofi-aventis U.S. LLCMultaq$591$97,196138 claims
MerckVerquvo, Januvia$739$70,21975 claims
Kowa Pharmaceuticals America, Inc.Livalo, Bystolic$839$52,586138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →